@ Vice
Danke für die Blumen.
Das sind nur versuche sich im Dschungel zurecht zu finden.:-)
andi84:
Hab von deiner Frage ja noch etwas überlesen.
21:47
#1346
Platinum resistent, heist sie haben Patienten genommen die vorher nicht auf diese Chemo angesprochen haben, beim Ovarkarzinom.
Sollte eigentlich keine Frage sein! :-)
Wusste nicht ob du daran denkst.
Recurrent ovarian cancer (potential platinum-sensitive) is defined as the recurrence of active disease in a patient who has achieved a documented response to initial platinum-based treatment and has been off therapy for an extended period of time. For the purposes of study design and interpretation, the Gynecologic Oncology Group (GOG) has divided “sensitive” from “resistant” disease at six months [5].
Resistant ovarian cancer is defined as disease that has responded to initial chemotherapy but demonstrates recurrence within a relatively short period of time following the completion of treatment. Again, GOG has decided that patients with documented recurrence within six months of completing initial therapy should be considered “platinum-resistant.”
Approach in Resistant/Refractory Disease
Patients with platinum-resistant ovarian cancer that did not respond to initial therapy, or with disease that recurred after a short (<six-month) treatment-free interval, pose a particular challenge. Similarly, patients with recurrent disease after retreatment with platinum-based therapy are often drug resistant, and may also be more difficult to treat due to cumulative hematologic and nonhematologic toxicity, as well as declining performance status due to persistent disease. However, there are a number of antineoplastic treatment options which may be considered based on recent clinical trials.
theoncologist.alphamedpress.org/content/5/1/26.full
www.ncbi.nlm.nih.gov/pubmed/23679331
Zurück
